Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Pipeline Review, H1 2015′, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview 9
Therapeutics Development 10
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Overview 10
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis 11
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics under Development by Companies 12
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Products under Development by Companies 18
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Companies Involved in Therapeutics Development 20
Altor BioScience Corporation 20
Amgen Inc. 21
Astellas Pharma Inc. 22
AstraZeneca Plc 23
ATLAB Pharma SAS 24
BIND Therapeutics, Inc. 25
Boehringer Ingelheim GmbH 26
Boston Biomedical, Inc. 27
Eli Lilly and Company 28
Exelixis, Inc. 29
Incyte Corporation 30
Johnson & Johnson 31
Merck & Co., Inc. 32
Mirati Therapeutics Inc. 33
Novartis AG 34
Pfizer Inc. 35
Sanofi 36
Sumitomo Dainippon Pharma Co., Ltd. 37
Teva Pharmaceutical Industries Limited 38
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
AdIL-24 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ALT-801 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AMG-228 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
amrubicin hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ATL-101 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AZD-4547 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
B-701 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BBI-503 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
buparlisib hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
cabazitaxel - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
cabozantinib s-malate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CEP-11981 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
docetaxel - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
enfortumab vedotin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
epacadostat - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
JNJ-42756493 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
mitomycin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
mocetinostat - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
nintedanib - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
palbociclib - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
pembrolizumab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
ramucirumab - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
SAR-408701 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
vandetanib - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Recent Pipeline Updates 114
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects 163
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products 164
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Product Development Milestones 165
Featured News & Press Releases 165
May 13, 2015: Mirati Therapeutics to Provide Updates on Mocetinostat at 2015 ASCO Annual Meeting 165
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting 165
Appendix 167
Methodology 167
Coverage 167
Secondary Research 167
Primary Research 167
Expert Panel Validation 167
Contact Us 167
Disclaimer 168

List of Tables

Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H1 2015 10
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Altor BioScience Corporation, H1 2015 20
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Amgen Inc., H1 2015 21
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Astellas Pharma Inc., H1 2015 22
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by AstraZeneca Plc, H1 2015 23
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by ATLAB Pharma SAS, H1 2015 24
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by BIND Therapeutics, Inc., H1 2015 25
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boehringer Ingelheim GmbH, H1 2015 26
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boston Biomedical, Inc., H1 2015 27
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Eli Lilly and Company, H1 2015 28
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Exelixis, Inc., H1 2015 29
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Incyte Corporation, H1 2015 30
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Johnson & Johnson, H1 2015 31
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Merck & Co., Inc., H1 2015 32
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Mirati Therapeutics Inc., H1 2015 33
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Novartis AG, H1 2015 34
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Pfizer Inc., H1 2015 35
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sanofi, H1 2015 36
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 37
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 44
Number of Products by Stage and Route of Administration, H1 2015 47
Number of Products by Stage and Molecule Type, H1 2015 49
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics - Recent Pipeline Updates, H1 2015 114
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects, H1 2015 163
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products, H1 2015 164

List of Figures

Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H1 2015 10
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 16
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Top 10 Targets, H1 2015 40
Number of Products by Stage and Top 10 Targets, H1 2015 40
Number of Products by Top 10 Mechanism of Actions, H1 2015 43
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43
Number of Products by Top 10 Routes of Administration, H1 2015 46
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46
Number of Products by Top 10 Molecule Types, H1 2015 48
Number of Products by Stage and Top 10 Molecule Types, H1 2015 48